Vericel (NASDAQ:VCEL) Director Robert Md Zerbe Sells 2,500 Shares of Company Stock

Vericel Corporation (NASDAQ:VCEL) Director Robert Md Zerbe sold 2,500 shares of the business’s stock in a transaction dated Wednesday, November 4th. The shares were sold at an average price of $45.40, for a total transaction of $113,500.00. Following the transaction, the director directly owned 32,995 shares in the company, valued at approximately $1,497,973. The trade was a 7.04% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Vericel Price Performance

Shares of VCEL traded up $2.84 during mid-day trading on Friday, reaching $54.62. The stock had a trading volume of 1,612,332 shares, compared to its average volume of 564,100. Vericel Corporation has a 52-week low of $28.95 and a 52-week high of $55.60. The business’s fifty day moving average is $41.01 and its 200 day moving average is $38.90. The firm has a market cap of $2.80 billion, a price-to-earnings ratio of 85.35 and a beta of 1.08.

Vericel (NASDAQ:VCEL) last issued its earnings results on Thursday, November 5th. The biotechnology company reported $0.27 EPS for the quarter, topping analysts’ consensus estimates of $0.06 by $0.21. The company had revenue of $85.37 million for the quarter, compared to the consensus estimate of $77.95 million. Vericel had a net margin of 7.91% and a return on equity of 6.91%. Vericel’s quarterly revenue was up 26.5% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.10 earnings per share. As a group, sell-side analysts anticipate that Vericel Corporation will post 0.54 EPS for the current fiscal year.

Hedge Funds Weigh In On Vericel

Hedge funds and other institutional investors have recently bought and sold shares of the company. Aberdeen Group plc lifted its position in shares of Vericel by 204.7% during the third quarter. Aberdeen Group plc now owns 2,164,250 shares of the biotechnology company’s stock worth $86,873,000 after purchasing an additional 1,454,012 shares in the last quarter. Allworth Financial LP grew its holdings in shares of Vericel by 53.0% in the third quarter. Allworth Financial LP now owns 2,052 shares of the biotechnology company’s stock valued at $91,000 after purchasing an additional 711 shares in the last quarter. Gagnon Securities LLC grew its holdings in shares of Vericel by 7.3% in the third quarter. Gagnon Securities LLC now owns 7,839 shares of the biotechnology company’s stock valued at $315,000 after purchasing an additional 536 shares in the last quarter. Maryland State Retirement & Pension System grew its holdings in shares of Vericel by 53.3% in the third quarter. Maryland State Retirement & Pension System now owns 11,395 shares of the biotechnology company’s stock valued at $457,000 after purchasing an additional 3,963 shares in the last quarter. Finally, Illinois Municipal Retirement Fund purchased a new stake in Vericel during the 3rd quarter worth approximately $1,071,000.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. TD Cowen upped their price objective on Vericel from $55.00 to $58.00 and gave the company a “buy” rating in a report on Friday, July 31st. Weiss Ratings restated a “hold (c)” rating on shares of Vericel in a research report on Thursday, October 29th. Canaccord Genuity Group set a $60.00 price target on Vericel in a research note on Thursday, July 30th. Truist Financial set a $65.00 price objective on Vericel in a research report on Friday. Finally, HC Wainwright boosted their price objective on shares of Vericel from $72.00 to $75.00 and gave the company a “buy” rating in a report on Friday. Four analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $60.80.

More Vericel News

Here are the key news stories impacting Vericel this week:

• Positive Sentiment: Vericel reported Q3 revenue of $85.4 million, up 26.5% year over year and above the $78.0 million consensus. Earnings per share of $0.27 also topped estimates of $0.06, while net income rose 179% to $14.2 million. Vericel Q3 results and guidance
• Positive Sentiment: The company raised its FY2026 revenue outlook to $344 million–$346 million, above analyst expectations of roughly $336 million, and lifted its adjusted EBITDA margin guidance to 28%. The stronger outlook, alongside record MACI sales, helped fuel investor optimism. Vericel shares rise on record revenue and higher outlook
• Positive Sentiment: HC Wainwright raised its price target to $75 from $72 and maintained a Buy rating, signaling continued analyst confidence in the stock’s prospects. HC Wainwright price target update
• Negative Sentiment: Several Vericel directors and insiders disclosed stock sales totaling about 22,000 shares on November 4–5. One insider’s sale reduced their reported stake by 88%, which may be a near-term concern for investors, though insider sales alone do not establish a negative outlook. SEC insider transaction filing

Vericel Company Profile

Vericel Corporation is a commercial-stage biopharmaceutical company focused on developing and marketing advanced cell therapies and regenerative medicine products. The company serves orthopedic and burn-care markets, with an emphasis on treatments that use a patient’s own cells or biologic materials to support tissue repair and healing.

Vericel’s primary orthopedic product is MACI, an autologous cultured chondrocyte implant used to repair symptomatic cartilage defects of the knee in adults.